Travoprost/verosudil

Drug Profile

Travoprost/verosudil

Alternative Names: AR-12286/travoprost; PG-286; Travoprost/AR-12286; Verosudil/travoprost

Latest Information Update: 27 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aerie Pharmaceuticals
  • Class Acetamides; Antiglaucomas; Antihypertensives; Isoquinolines; Prostaglandins; Small molecules; Thiophenes
  • Mechanism of Action Prostaglandin F2 alpha agonists; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma; Ocular hypertension

Most Recent Events

  • 30 Jun 2013 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)
  • 30 Jun 2013 Discontinued - Phase-II for Ocular hypertension in USA (Ophthalmic)
  • 27 Feb 2013 Aerie Pharmaceuticals initiates enrolment in a phase IIb trial for Glaucoma or Ocular hypertension in USA (NCT01789736)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top